Oxford Biomedica Share Discussion Threads

[badger60] 29/6/2022 15:38

DC
I'm starting to realise why they call it OxBox.
Let's hope that the name isn't a precise description of what it's (not) good for at generating significant revenue, ie. the purpose for which it was constructed (hopefully!) and not become a financial millstone around shareholders necks........like Homology is........

[marcusl2] 29/6/2022 11:51

Oxford Biomedica
@OxfordBiomedica

It is now fully apparent that product quality is critical to the performance of #GeneTherapy products.

In this webcast, Tim Kelly (CEO of #OXB Solutions) describes how we ensure our AAV platform delivers products that meet the highest quality standards.

[badger60] 29/6/2022 10:03

DC Well stop doing it then........

[dominiccummings] 29/6/2022 09:45

Repeating rubbish does not make it fact

[badger60] 29/6/2022 09:41

DCSo this is how "Wealth Management" works........and you pay for it as well??? Looking at Diggle's track record he should cancel his subscription.........

[badger60] 29/6/2022 08:46

Poor old Harry and his "bots". Those "bots" have much to answer for.........about a13 quid depletion of the OXB share price in 10 months.I don't know about "Vulpes"......... "Gulpes" would be far more apt imo.

[harry s truman] 29/6/2022 08:35

The bots are back. More trades in 30mins this morning than until 2pm yesterday and down 5%. OXB have one more day to get some more news in the first half.

[badger60] 29/6/2022 08:20

DC
OXB need sizable cash paying contracts quickly. They must have loads of spare capacity, especially after losing the very lucrative AZN Vax production contract.
All Homology seem to want to do is hire more staff and spend more money (according to their web site 1st QTR result news item).
It looks like Diggle is trying to prop up the OBD share price ......not surprising given the 90,000 GBP in revenue for 6 months, after the product launch!, and cash burn in excess of 4 Mio for the period.

[marcusl2] 29/6/2022 07:55

Renal cell carcinoma

This finding indicates that 5T4 may be a potential target antigen for TCR-T cell therapy in RCC. Similarly, more in vitro and in vivo studies are needed to evaluate the efficacy and safety of 5T4-specific TCR-T cells in the treatment of RCC.

[marcusl2] 29/6/2022 07:53

current TCR-T cell advances and their potential advantages for solid tumor immunotherapy



1st CAR-T/TCR-T
(Bristol Myers Squibb) (Juno)

Undisclosed Phase I
2nd CAR-T/TCR-T
(Bristol Myers Squibb)

Undisclosed Pre-Clinical
3rd CAR-T/TCR-T
(Bristol Myers Squibb)

Undisclosed Pre-Clinical
4th CAR-T/TCR-T
(Bristol Myers Squibb)

[badger60] 29/6/2022 00:19

DCOh dear....have you seen OBD, the latest Diggle disaster imploding because of high cash burn and no revenue (90 thousand quid in 6 months earned!....with a 4+ Mio cash burn (again)).Well you can thank OXB inept management for steering the company in the same direction as OBD. If substantial revenue is not generated here, and relatively quickly, the combined US/UK overhead will bury this company.The problem is that they don't know how to put the (cash) brakes on because the inept management have created a vehicle without any................

[marcusl2] 28/6/2022 21:18

Novartis recently brought in Ronny Gal, the former Bernstein analyst, to spearhead M&A as its chief strategy and growth officer. The company is eyeing deals worth around $2 billion or below, CEO Vas Narasimhan has said.

[gareth jones] 28/6/2022 15:05

Does the share price get a small lift around 2pm to 2.30pm or is that just my imagination? As an aside, in Sunday School (William King, Dursley, Robert Raikes, Gloucester) we used to sing “we are climbing Jacob’s ladder… each day takes us one step higher, higher..etc” perhaps it could be re-phrased? Last Latin quote from a Comprehensive schoolboy…Carpe Diem!

[dominiccummings] 28/6/2022 13:34

wrong thread... oops

[dominiccummings] 28/6/2022 13:26

Broken fred...

[dominiccummings] 28/6/2022 13:23

If I had written the bot's program I would build in a wait when turnover is light to see which way the share price 'wants to go', then trade that direction.

[harry s truman] 28/6/2022 12:35

5,814 shares traded so far today (£28k) which genuinely is next to nothing for OXB. I'm sure there is a reason why the bots aren't churning away at their usual rate, but I don't know what it might be.

[marcusl2] 28/6/2022 10:18

Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens

[badger60] 28/6/2022 09:33

Anything significantly revenue generating would be shouted out about from the rooftops. My guess is most if not all OXB revenue is too small or embarrassing to talk about. And nothing as yet from Homology except nearly a 40 Mio USD running cost loss in the first 3 months of this year.

[gigabit] 28/6/2022 09:21

The Juno approval from the FDA is obviously potential good news but the absence of any comment from OXB implies that they expect the revenue impact to be insignificant. If it were a major revenue boost it would warrant, even require, a RNS.

[badger60] 28/6/2022 08:24

DC
Unfortunately the silence from the inept OXB management is deafening............a bit like waiting to be told your turn on death row......

[marcusl2] 27/6/2022 20:45

The pound is weak also.

[harry s truman] 27/6/2022 14:53

There is a lot of money about Marcus - particularly with companies who did very well out of coronavirus and are positioning now for another season in the northern hemisphere.

Oh for a crystal ball eh? (or a time machine).